Abstract | OBJECTIVE: METHODS: RESULTS: The primary outcome measure, change in score on the International Restless Legs Syndrome Scale, showed a statistically significant improvement in RLS during the first 4 weeks after treatment. Two of the secondary outcome measures, pain (measured using a visual analog scale) and patients' global impression of severity of illness also showed improvement. CONCLUSIONS:
Onabotulinum toxin A warrants further study in RLS. Increasing the drug dosage, changing the dosing schedule, and increasing the number of injection sites may result in greater activity and longer duration of action.
|
Authors | Pinky Agarwal, Cherri Sia, Narendra Vaish, Ina Roy-Faderman |
Journal | The International journal of neuroscience
(Int J Neurosci)
Vol. 121
Issue 11
Pg. 622-5
(Nov 2011)
ISSN: 1563-5279 [Electronic] England |
PMID | 21740308
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Botulinum Toxins, Type A
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Neuromuscular Agents
(administration & dosage, adverse effects)
- Patient Satisfaction
- Pilot Projects
- Restless Legs Syndrome
(drug therapy, physiopathology)
- Severity of Illness Index
- Sleep Wake Disorders
(drug therapy, etiology, physiopathology)
- Young Adult
|